SEARCH

SEARCH BY CITATION

References

  • 1
    Kane MA. Progress on the control of hepatitis B infection through immunisation. Gut 1993; 34(Suppl):10S12S.
  • 2
    Rustgi VK, Hoofnagle JH, Gerin JL, Gelmann EP, Reichert CM, Cooper JN, Macher AM, et al. Hepatitis B infection in the acquired immunodeficiency syndrome. Ann Intern Med 1984; 101:795797. MEDLINE
  • 3
    de Jongh FE, Janssen HL, de Man RA, Hop WC, Schalm SW, van Blankenstein M. Survival and prognostic indicators of hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992; 103:16301635. MEDLINE
  • 4
    Weissberg JI, Andres LL, Smith CI, Weick S, Nichols JE, Garcia G, et al. Survival in chronic hepatitis B. Ann Intern Med 1984; 101:613616. MEDLINE
  • 5
    Perrillo RP, Regenstein FG, Roodman ST. Chronic hepatitis B in asymptomatic homosexual men with antibody to the human immunodeficiency virus. Ann Intern Med 1986; 105:382383. MEDLINE
  • 6
    MacDonald JA, Caruso L, Karayannis P, Scully J, Harris JRW, Forster GE, Thomas HC, et al. Diminished responsiveness of male homosexual chronic hepatitis B virus carriers with HTLV III antibodies to recombinant alpha interferon. Hepatology 1987; 7:719723. MEDLINE
  • 7
    Wong DK, Yim C, Naylor CD, Chen E, Sherman M, Vas S, Wanless IR, et al. Interferon alfa treatment of chronic hepatitis B: randomized trial in a predominantly homosexual male population. Gastroenterology 1995; 108:165171. MEDLINE
  • 8
    Lai CL, Chien RN, Leung NWY, Chang TT, Guan R, Tai DI, Ng KY, et al. A one year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339:6168. MEDLINE
  • 9
    Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin R. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333:16571661. MEDLINE
  • 10
    Benhamou Y, Katlama C, Lunel F, Coutellier A, Dohin E, Hamm N, Tubiana R, et al. The effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Intern Med 1996; 125:705712. MEDLINE
  • 11
    Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, Hawley S, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999; 29:889896. MEDLINE
  • 12
    Tripples GA, Ma MM, Fisher KP, Bain VG, Kneteman M, Tyrrell DLJ. Mutation in HBV-DNA-dependent polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 24:714717. MEDLINE
  • 13
    Bartholomew MM, Jansen RW, Lennox JJ, Jeffers J, Reddy KR, Johnson LC, Condreay LD, et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 349:2022. MEDLINE
  • 14
    Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, Harrison TJ. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996; 24:37113713.
  • 15
    Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998; 27:16701677. MEDLINE
  • 16
    Chayama K, Suzuki Y, Kobayashi M, Kobayashi M, Tsubota A, Hashimoto M, Miyano Y, et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998; 27:17111716. MEDLINE
  • 17
    Niesters HG, Honkoop P, Haagsma EB, de Man RA, Schalm SW, Osterhaus AD. Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment. J Infect Dis 1998; 177:13821385. MEDLINE
  • 18
    Pillay D, Bartholomeusz A, Cane P, Mutimer D, Schinazi RF, Locarnini S. Mutations in the hepatitis B virus DNA polymerase associated with antiviral resistance. Int Antiviral News 1998; 6:167169.
  • 19
    Center for Disease Control. 1993 Revised classification system for HIV infection and expanded AIDS surveillance case definition for adolescents and adults. Mor Mortal Wkly Rep CDC Surveill Summ 1992; 41: 24, 14–15.
  • 20
    Tisdale M, Kemp SD, Parry NR, Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA 1993; 90:56535656. MEDLINE
  • 21
    Wainberg MA, Salomon H, Gu Z, Montaner JS, Cooley TP, McCaffrey R, Ruedy J, et al. Development of HIV-1 resistance to (2′-deoxy-3′-thiacytidine) in patients with AIDS or advanced AIDS-related complex. AIDS 1995; 9:351357. MEDLINE
  • 22
    Back NK, Nijhuis M, Keulen W, Boucher CA, Oude Essink BO, van Kuilenburg AB, van Gennip AH, et al. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J 1996; 15:40404049. MEDLINE
  • 23
    Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, Vidaud M, et al. Liver fibrosis progression in HIV and HCV coinfected patients. Hepatology 1999; 30:10541058. MEDLINE
  • 24
    Colin JF, Cazals-Hatem D, Loriot MA, Martinot-Peignoux M, Pham BN, Auperin A, Degott C, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999; 29:13061310. MEDLINE